These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1344 related articles for article (PubMed ID: 25857211)
81. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. Elajami TK; Colas RA; Dalli J; Chiang N; Serhan CN; Welty FK FASEB J; 2016 Aug; 30(8):2792-801. PubMed ID: 27121596 [TBL] [Abstract][Full Text] [Related]
82. Resolvins and protectins: mediating solutions to inflammation. Kohli P; Levy BD Br J Pharmacol; 2009 Oct; 158(4):960-71. PubMed ID: 19594757 [TBL] [Abstract][Full Text] [Related]
83. Roles of resolvins in the resolution of acute inflammation. Qu Q; Xuan W; Fan GH Cell Biol Int; 2015 Jan; 39(1):3-22. PubMed ID: 25052386 [TBL] [Abstract][Full Text] [Related]
84. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications. Valente M; Dentoni M; Bellizzi F; Kuris F; Gigli GL Molecules; 2022 Jul; 27(15):. PubMed ID: 35956787 [TBL] [Abstract][Full Text] [Related]
85. Resolution of inflammation as a novel chemopreventive strategy. Lee HN; Na HK; Surh YJ Semin Immunopathol; 2013 Mar; 35(2):151-61. PubMed ID: 23370700 [TBL] [Abstract][Full Text] [Related]
86. Role of Specialized Pro-Resolving Mediators in Modifying Host Defense and Decreasing Bacterial Virulence. Thornton JM; Yin K Molecules; 2021 Nov; 26(22):. PubMed ID: 34834062 [TBL] [Abstract][Full Text] [Related]
87. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. Serhan CN FASEB J; 2017 Apr; 31(4):1273-1288. PubMed ID: 28087575 [TBL] [Abstract][Full Text] [Related]
88. Endogenous lipid mediators in the resolution of airway inflammation. Haworth O; Levy BD Eur Respir J; 2007 Nov; 30(5):980-92. PubMed ID: 17978156 [TBL] [Abstract][Full Text] [Related]
89. Endogenous pro-resolving and anti-inflammatory lipid mediators: the new hope of atherosclerotic diseases. Chen Y; Wang J; Nie R; Zhou S Med Hypotheses; 2008 Aug; 71(2):237-40. PubMed ID: 18448265 [TBL] [Abstract][Full Text] [Related]
90. Pharmacological effects of specialized pro-resolving mediators in sepsis-induced organ dysfunction: a narrative review. Sun S; Yang D; Lv J; Xia H; Mao Z; Chen X; Gao Y Front Immunol; 2024; 15():1444740. PubMed ID: 39372413 [TBL] [Abstract][Full Text] [Related]
91. Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases. Giudetti AM; Cagnazzo R Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):57-67. PubMed ID: 23064030 [TBL] [Abstract][Full Text] [Related]
92. Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Poulsen RC; Gotlinger KH; Serhan CN; Kruger MC Am J Hematol; 2008 Jun; 83(6):437-45. PubMed ID: 18429055 [TBL] [Abstract][Full Text] [Related]
93. New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution. Prevete N; Liotti F; Amoresano A; Pucci P; de Paulis A; Melillo RM Pharmacol Res; 2018 Feb; 128():80-87. PubMed ID: 28986132 [TBL] [Abstract][Full Text] [Related]
94. Does the use of specialized proresolving molecules in critical care offer a more focused approach to controlling inflammation than that of fish oils? Martindale RG; Warren MM; McClave SA Curr Opin Clin Nutr Metab Care; 2016 Mar; 19(2):151-4. PubMed ID: 26828585 [TBL] [Abstract][Full Text] [Related]
95. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Weylandt KH; Chiu CY; Gomolka B; Waechter SF; Wiedenmann B Prostaglandins Other Lipid Mediat; 2012 Mar; 97(3-4):73-82. PubMed ID: 22326554 [TBL] [Abstract][Full Text] [Related]
97. Pro-resolving and anti-inflammatory effects of resolvins and protectins in rheumatoid arthritis. Zhang X; Zhang H Inflammopharmacology; 2023 Dec; 31(6):2995-3004. PubMed ID: 37831392 [TBL] [Abstract][Full Text] [Related]
98. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Fredman G; Serhan CN Biochem J; 2011 Jul; 437(2):185-97. PubMed ID: 21711247 [TBL] [Abstract][Full Text] [Related]
99. Resolvins: Current understanding and future potential in the control of inflammation. Bannenberg GL Curr Opin Drug Discov Devel; 2009 Sep; 12(5):644-58. PubMed ID: 19736623 [TBL] [Abstract][Full Text] [Related]
100. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy? Chávez-Castillo M; Ortega Á; Cudris-Torres L; Duran P; Rojas M; Manzano A; Garrido B; Salazar J; Silva A; Rojas-Gomez DM; De Sanctis JB; Bermúdez V Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638711 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]